Japan indapamide market is estimated to grow at a CAGR of around 1.7% during the forecast period. The growth is attributed to the rising number of hypertension and diabetes patients in the country. As per the IDF, in 2019, the total cases of diabetes in adults were 7.4 million, which accounted for nearly 7.9% of the total adult population in the country. The factors that are contributing to the increasing prevalence of diabetes include the presence of a significant obese population. As per the World Bank, between 1997 and 2016, in Japan, the prevalence of obesity, male (% of male population ages 18+) increased substantially from 1.6% to 4.8%. As per the National Health Service (NHS), individuals with hypertension were found to have a risk of more than 70% of developing type 2 diabetes. Therefore, it is expected that a significant number of diabetes patients may also have hypertension in the country which may increase the possibility of severe conditions, including heart failure and kidney diseases. This, in turn, will likely drive the demand for indapamide in the country.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/japan-indapamide-market
Japan indapamide market is segmented on the basis of product and application. Based on the product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held a significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have a significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
The companies which are contributing to the growth of the Japan indapamide market include Glenmark Pharmaceuticals Ltd, Shandong Yinfeida Pharmaceutical Co., Ltd., Suzhou Lixin Pharmaceutical Co., Ltd., Merck KGaA, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market.
Japan Indapamide Market- Segmentation
By Product
- 25 MG
- 5 MG
By Application
- High Blood Pressure
- Heart Failure
- Others
A full report of Japan Indapamide Market is available at: https://www.omrglobal.com/industry-reports/japan-indapamide-market
